Toward better evidence: Meta-analysis of vascular endothelial growth factor (VEGF) polymorphisms in retinopathy of prematurity  by Al-Abdullah, Abdulelah A. & Kozak, Igor
Saudi Journal of Ophthalmology (2014) 28, 251—252EditorialToward better evidence: Meta-analysis of vascular endothelial
growth factor (VEGF) polymorphisms in retinopathy of
prematurityPeer review under responsibility
of Saudi Ophthalmological Society,
King Saud University Production and hosting by Elsevier
Access this article onlin
www.saudiophthaljourn
www.sciencedirect.comThough meta-analysis is ranked in the top of the evidence
based medicine pyramid, some aspects of meta-analysis
seem mysterious in nature. By definition, meta-analysis is a
statistical method for combining the results of several inde-
pendent studies addressing similar hypotheses in order to
gain a better estimate of the effect size of an intervention.1
Meta coming from the Greek prefix ‘‘meta’’ means ‘‘after’’
or ‘‘beyond’’. Thus, the idea is to pool the results of two stud-
ies or more in order to look beyond the primary results of the
individual studies. The combined result can be evaluated as a
secondary outcome using one of the size effect measures
such as odds ratio, relative risk, and mean difference. In order
to produce useful and meaningful results out of meta-analy-
sis, a good systematic review should take place first. System-
atic review is an integral part of any meta-analysis which
started with an appropriate research question followed by a
systematic retrieval of relevant studies through pre-planned
inclusion and exclusion criteria. Summarizing the characteris-
tics of the included studies concludes a systematic review.
Subsequently, statistical analysis of the pooled results pro-
vides us with meta-analysis.
The number of published systematic reviews and meta-
analyses in ophthalmic field has been increasing progres-
sively over the past years. The number of publications
increased from 3 per year in 1994 to almost 100 per year in
2010.2 This increased publication reflects the need for such
design, especially with presence of several studies on the
effect of an intervention or risk factor with varying directions
or varying significance of outcome. Meta-analysis helps to
interpret and clarify the direction and magnitude of the size
effect. The major ophthalmic subspecialties that publish sys-
tematic reviews and meta-analyses are retina which repre-
sents 35% of the publication of this type followed by
glaucoma with publication rate of 21%.2
In this journal issue, another retinal meta-analysis discusses
the risk and contributing impact of a specific vascular endo-
thelial growth factor (VEGF) polymorphism on retinopathy
of prematurity (ROP).3 It has been known that the retinopathy
of prematurity is a major cause of childhood blindness. In
Saudi Arabia, retinopathy of prematurity was found to be
comparable to reports from other parts of the world. In a
cohort of premature infants with a mean gestational age of
28.4 weeks, the incidence of ROP with birth weight of
<1500 grams and <1250 grams was 41% and 50.7%, respec-tively. Nineteen of the 73 children with ROP (26%) reached
threshold ROP, and needed laser treatment or cryotherapy.4
Development of ROP passes through two phases. In the first,
the relative high oxygen inhibits the physiologically driven
retinal vascularization by inhibiting the normal vascular endo-
thelial growth factor (VEGF) secretion which is a hypoxia-
inducible cytokine. In the second, there is relative hypoxia
as a result of increased metabolic demand in the process of
retinal maturation.5 Hypoxia promotes high-expression of
VEGF and stimulates abnormal retinal vasculogenesis leading
to the clinical manifestations of ROP such as neovasculariza-
tion and proliferative retinopathy. Thus, VEGF is a key in nor-
mal and pathological retinal vascularization.
Many researchers believe that single nucleotide polymor-
phisms (SNPs) of VEGF are related to the changes of protein
expression during ROP and hence the susceptibility to
develop ROP. However in case of the single nucleotide poly-
morphisms at positions rs 2010963, there are conflicting
results concerning the direction of impact of VEGF polymor-
phism on ROP risk. Malik et al., in this issue, employed meta-
analysis to show that VEGF-634G/C (rs 2010963) polymor-
phism may not be associated with ROP risk based on the
pool results of six case-control studies including 355 cases
and 471 controls.3 The pooled results of these studies in
meta-analysis help to increase the sample size and improve
the statistical power compared to the individual studies.
The current study analyzed the association between VEGF-
634G/C polymorphism and ROP risk using different models
(dominant versus recessive) at different levels (allele versus
ethnicity level) to provide more convincing result. The lack
of association between VEGF-634G/C polymorphism and
ROP risk is in agreement with previous meta-analysis by Liu
et al. who demonstrates that advanced ROP is not associated
with VEGF gene –634G/C polymorphism.6
As with other scientific reports, meta-analysis can also suf-
fer from potential bias which should not be overlooked. Pub-
lication bias occurs when the studies with positive and
statistically significant results are more likely to be published
and negative studies never make it to scientific literature. The
most common method in the detection of publication bias is
a ‘‘funnel plot’’. However, in the presence of small number of
the included studies, such as here, it might be difficult to
interpret funnel plot. Moreover, when publications address
largely different populations funnel plot may give a wronge:
al.com
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‘‘Egger’s plot’’ is used to quantify the potential presence of
publication bias which helps to recognize such bias.8 Other
sources of bias include the limited data from ethnic groups
in the pooled result and presence of heterogeneity among
the individual studies in the methods used for genotyping.
The current study consolidates knowledge on previously
believed one specific VEGF-driven risk factor for ROP. As
such, it brings current understanding of this topic to a new
level of our evidence-based pyramid knowledge. Due to
the accumulated evidence of the role of VEGF in ROP, we
believe that search for other potential polymorphisms in
VEGF family or other related pathways may continue. It is
possible, however, that a larger sample size, more racial
and ethnic groups and comprehensive consideration of other
related factors are required to have a better understanding
of the association between the VEGF polymorphisms and risk
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